• Business
  • Economy
  • Real Estate
  • Tech
  • World News
  • Markets
  • Scam Alerts
  • CDI Calculator
Sign in
Welcome!Log into your account
Forgot your password?
Privacy Policy
Password recovery
Recover your password
Search
Wednesday, February 1, 2023
  • Contact
  • About Us
  • Privacy Policy
Sign in
Welcome! Log into your account
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
A password will be e-mailed to you.
investors diurnal financial news magazine Investors Diurnal Finance Magazine
investors diurnal financial news magazine investors diurnal financial news magazine
  • Business
  • Economy
  • Real Estate
  • Tech
  • World News
  • Markets
  • Scam Alerts
  • CDI Calculator
Home Markets Latest news updates: Asos chief Nick Beighton to step down – Financial...
  • Markets

Latest news updates: Asos chief Nick Beighton to step down – Financial Times

October 11, 2021
6
Facebook
Twitter
WhatsApp
Linkedin
Email

    Latest news updates: Asos chief Nick Beighton to step down  Financial Times

    Click here for full article…www.ft.com

    Facebook
    Twitter
    WhatsApp
    Linkedin
    Email
      Investors Diurnal Team
      163FansLike

      EDITOR PICKS

      Student of the Week Springfield-Clark Career Technology Center

      Investors Diurnal Team - April 17, 2022

      Decoupling is the last thing on business leaders’ minds

      Investors Diurnal Team - November 25, 2021

      Metro Bank : Twelve Scams of Christmas

      Investors Diurnal Team - December 10, 2021

      Bendigo small business falls victim to shipping container scam, and it’s not alone

      Investors Diurnal Team - September 2, 2021

      South African rand falls as dollar gains on Fed expectations

      Investors Diurnal Team - September 29, 2021

      Construction on key Northeast corridor rail bridge gets OK’d | Ap

      Investors Diurnal Team - April 7, 2022
      Investors Diurnal financial news magazine - global asset management
      News, market analysis, investment scam prevention tips and more. Investors Diurnal is your financial and world news website. Get the latest breaking news 27/4 from all over the globe. Your ticket to successful wealth management.
      Contact us: info@investorsdiurnal.com

      EVEN MORE NEWS

      Letters to the Editor | News, Sports, Jobs – The Sentinel...

      February 1, 2023

      There is no way for easy money

      February 1, 2023

      Westfield woman heartbroken after losing $98K to romance scam

      January 31, 2023

      POPULAR CATEGORY

      • Scam/Fraud4962
      • World News2494
      • Markets2407
      • Business2269
      • Economy2127
      • Tech2053
      • Real Estate2012
      • About Us
      • Contact
      • Privacy Policy
      • sitemap
      investorsdiurnal.com © all rights reserved 2020

      Accessibility

        • visibility_offDisable flashes

        • titleMark headings

        • settingsBackground Color

        • zoom_outZoom out

        • zoom_inZoom in

        • remove_circle_outlineDecrease font

        • add_circle_outlineIncrease font

        • spellcheckReadable font

        • brightness_highBright contrast

        • brightness_lowDark contrast

        • format_underlinedUnderline links

        • font_downloadMark links

        • Reset all optionscached

        • Accessibility Light
      MORE STORIES
      Markets

      UPDATE 2-IAEA will have no access to Iran’s nuclear sites images,...

      Investors Diurnal Team - May 23, 2021 0
      The ConversationRepresentative Cheney calls for orderRep. Liz Cheney, Republican of Wyoming, speaks to the press at the U.S. Capitol in Washington, D.C., on May...
      investorsdiurnal business news magazine
      Markets

      Novadoz Has a Fast Start to 2021 with Generic Launches of...

      Investors Diurnal Team - April 23, 2021 0
      PISCATAWAY, N.J., April 23, 2021 /PRNewswire/ -- MSN Labs, based in Hyderabad, India, received FDA approval to market their generic versions of Albendazole 200mg tablets (AB rated to Albenza©), Droxidopa 100mg, 200mg, 300mg capsules (AB rated to Northera ©), Deferasirox Granules 180mg, 360mg sachets (AB rated to Jadenu Sprinkles©) and Pregabalin ER 82.5mg, 165mg, 330mg tablets, (AB rated to Lyrica CR©) under the Novadoz label.  Novadoz is the U.S sales and marketing affiliate for MSN's portfolio of finished dosage forms. The company has commenced shipping of all the products which received approvals during Q1 2021.Albendazole 200mg is marketed in bottles of 2 tablets.  It is indicated for the treatment of neurocysticercosis which is an infection caused by the pork tapeworm in the muscles, brain, and eyes that may cause seizures, brain swelling, and vision problems. The most recent 12 month published sales of the brand and generics total $26.9mil.Droxidopa 100mg, 200mg, & 300mg are available in bottles of 30 capsules.  It is indicated for the symptomatic treatment of dizziness, lightheadedness, or fainting/black out sensation due to neurogenic orthostatic hypotension (a sudden fall in blood pressure). Novadoz participated in a Day 1 launch of the product, coinciding with the expiration of the brand exclusivity. Previous 12 month published sales for the brand totaled $366mil.  Novadoz has also offered a patient e-voucher assistance plan for those qualified consumers needing aid to cover their out of pocket prescription co-pay costs for Droxidopa.  Visit NovadozPharma.com to learn more information on the program.Among their recent FDA approvals include niche products, Deferasirox Granules 180mg, and 360mg that are available in a carton of 30 sachets. The product is used treat ongoing high levels of iron in the body caused by multiple blood transfusions. It is also used to treat high levels of iron in people with a certain blood disorder who do not require blood transfusions. The other niche offering includes Pregabalin ER 82.5mg, 165mg, and 330mg tablets available in bottles of 30.  The product is indicated for the treatment of pain caused by nerve damage due to diabetes or shingles (herpes zoster). Seshu Akula, Novadoz President North America Generics, states, "The first quarter of 2021 was a very active period for the MSN/Novadoz organization with four FDA approvals. We successfully introduced these products to the market, while keeping pace with the high demand for our existing product line created by the pandemic."He adds, "MSN's position as a global leader in APIs has provided Novadoz with the scale and leveraged strength comparable to some of the largest generic pharma companies in the U.S.  We are well positioned in the generic industry with a deep pipeline of oral solids, injectable, and specialty products that we expect to launch over the next 10 years."MSN Labs is engaged in the development and manufacturing of API (active pharmaceutical ingredients), KSMs (key starting materials), and product intermediates.  MSN is a global leader in this category. Additionally, the company also manufactures oral solids, liquids, and specialty injectable products in sixty-five markets throughout the world, doing business in the U.S. as Novadoz Pharmaceuticals.For more information, visit the company's websites at NovadozPharma.com & MSNLabs.com.CONTACT:Tom DeStefanoNovadoz Pharmaceuticals Vice President Sales and Marketing (848) 200-1909 View original content to download multimedia:https://www.prnewswire.com/news-releases/novadoz-has-a-fast-start-to-2021-with-generic-launches-of-albendazole-droxidopa-deferasirox-granules-and-pregabalin-er-301275804.htmlSOURCE Novadoz Pharmaceuticals
      Markets

      What Will It Take To Get Inflation Down? Is Oil The...

      Investors Diurnal Team - June 11, 2022 0
      WASHINGTON, DC - MARCH 14: Prices for gas at an Exxon gas station on Capitol...